Levetiracetam Eignapharma

Levetiracetam, the active ingredient in Levetiracetam Eignapharma, is an anticonvulsant presented as an injection for intravenous use. It treats epilepsy, including partial‑onset seizures and generalized tonic‑clonic seizures, in adults and children as prescribed, offering a rapid onset of action for acute seizure control.

GNH USA supplies Levetiracetam Eignapharma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics across Europe, Asia, Africa and the Americas, ensuring consistent quality and regulatory compliance for global healthcare providers.

Levetiracetam is an antiepileptic drug used to manage seizure disorders by stabilizing neuronal activity.

Epilepsy: reduces overall seizure frequency in patients with generalized or focal epilepsy. Partial‑onset seizures: controls focal seizure activity and prevents progression. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with this seizure type.

Levetiracetam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis or angioedema - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Blood dyscrasias including neutropenia or thrombocytopenia - Suicidal thoughts or behavior - Severe skin rash - Rare respiratory depression

When prescribing Levetiracetam, clinicians should consider several safety precautions to optimize therapy and minimize risk.

Renal impairment: dose adjustment may be required based on creatinine clearance. Hepatic dysfunction: monitor liver function tests periodically. Concomitant CNS depressants: increased sedation risk, monitor patient response. Pregnancy: potential unknown risks; discuss benefits and alternatives with the patient. Driving and operating machinery: may cause drowsiness; advise caution. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, influencing its plasma concentration or enhancing side‑effects.

Major Interactions (Avoid): - Carbamazepine: enzyme induction reduces levetiracetam levels. - Phenytoin: may lower levetiracetam exposure. - Phenobarbital: can decrease therapeutic concentration.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam plasma levels. - Topiramate: additive CNS depression possible. - Alcohol: enhances sedative effects, monitor for excessive drowsiness.